Antibody for treating or preventing senile dementia, its expression vector and application in drug preparation

An expression vector and senile technology, applied in the field of genetic engineering, can solve the problems of restricting application, increasing the clearance rate of mouse-derived monoclonal antibody, and reducing the antibody titer

Inactive Publication Date: 2006-07-19
NANJING MEDICAL UNIV
View PDF0 Cites 27 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] However, the existing reports mostly use mouse-derived monoclonal antibody, which is a foreign protein for the human body and can cause the human immune system to produce human anti-mouse antibody (HAMA), which largely limits its use in the human body. App

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antibody for treating or preventing senile dementia, its expression vector and application in drug preparation
  • Antibody for treating or preventing senile dementia, its expression vector and application in drug preparation
  • Antibody for treating or preventing senile dementia, its expression vector and application in drug preparation

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0038] Preparation method and identification experiment:

[0039] (1) Amplification of the human phage antibody library:

[0040] 1. The Griffin.1 phage display human single-chain antibody library (about 1×10 10 Clones) were inoculated into 500ml 2×TY-AMP-GLU medium, cultured at 37°C with shaking at 220rpm until OD 600 It is 0.5 (about 1.5-2h).

[0041] 2. Take 25ml culture medium (about 1×10 10 bacteria), superinfected with M13K07 helper phage. The infection ratio was 1:20 (number of bacteria: number of helper phages). In a 37°C water bath, let stand for 30 minutes.

[0042] 3. Centrifuge at 3300g at 4°C for 10 minutes, and resuspend the pellet with 30ml 2×TY-AMP-KAN medium.

[0043] 4. Add the bacterial liquid to 470ml of pre-warmed 2×TY-AMP-KAN medium, culture at 30°C and shake at 220rpm overnight.

[0044] 5. Centrifuge at 10800g at 4°C for 10min, and discard the precipitate.

[0045] 6. Collect the supernatant, add 1 / 5 supernatant volume of PEG / NaCl (20% polyethylen...

Embodiment 2

[0292] Embodiment 2: the preparation of pharmaceutical composition

[0293]A therapeutically effective amount of the antibody of the present invention (SEQ ID No.2) or its expression vector (including but not limited to plasmid, phagemid, phage, Escherichia coli, the same below), or the nucleotide encoding the antibody (SEQ ID No. No.1) or its expression vectors are used alone or mixed with pharmaceutically acceptable adjuvants to form a pharmaceutical composition. The pharmaceutical composition can be used alone or mixed with other drugs that do not affect the function of the pharmaceutical composition. The preparation of these pharmaceutical compositions can be in any pharmaceutically acceptable dosage form, including but not limited to tablets, pills, capsules, injections, oral liquids or liposomes. Methods for the preparation of these formulations are well known to those of ordinary skill in the art. These pharmaceutical compositions can be used for treating or preventing...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Upstream primeraaaaaaaaaa
Login to view more

Abstract

The disclosed antibody special for beta-amyloid polypeptide has amino acid sequence and the coded nucleotide sequence shown as SEQ ID No.2 and SEQ ID No.1 respectively, and can be used to prepare drug to cure or prevent senile dementia.

Description

technical field [0001] The invention belongs to the field of genetic engineering and relates to an antibody for treating or preventing senile dementia. The invention also relates to the expression vector of the antibody and their application in pharmacy. Background technique [0002] Senile dementia, also known as Alzheimer's disease (AD), is a neurodegenerative disease that seriously endangers human health and is one of the most common forms of senile dementia. AD patients are mainly manifested as memory loss, cognitive impairment and loss of spatial discrimination ability, and even motor and sensory dysfunction, seizures and other symptoms in the late stage of the disease. At present, the incidence of AD in the world is as high as 12 million, and it shows a trend of increasing year by year. At present, there are mainly five clinical methods for the treatment of AD: one is to protect the nerves from damage, the other is to use cholinesterase inhibitors to prevent the loss ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07K16/18C12N15/63C12N15/13A61K39/395A61P25/28
Inventor 陈琪乐珅李玥夏骏
Owner NANJING MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap